ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

バゼドキシフェン

Bazedoxifene

HCID 154257
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
198481-32-2
標準SMILES
Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12
InChIKey
UCJGJABZCDBEDK-UHFFFAOYSA-N
分子式
C30H34N2O3
平均分子量
470.6 g/mol
単同位体質量
470.25694295

概要

Bazedoxifene is a phenylindole.

名称と識別子

優先名称
Bazedoxifene
IUPAC
1-[[4-[2-(azepan-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methylindol-5-ol
現地名
バゼドキシフェン
英語名
Bazedoxifene
分子式
C30H34N2O3
分子量
470.6

名称と別名

Bazedoxifene198481-32-2ConbrizaBazedoxifenoTSE-424bazedoxifenumQ16TT9C5BKWAY 1404241-[[4-[2-(azepan-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methylindol-5-ol1H-Indol-5-ol, 1-[[4-[2-(hexahydro-1H-azepin-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methyl-DTXSID70173593TSE424
名称をさらに表示
1-[4-[2-(ヘキサヒドロ-1H-アゼピン-1-イル)エトキシ]ベンジル]-2-(4-ヒドロキシフェニル)-3-メチル-1H-インドール-5-オール1-({4-[2-(アゼパン-1-イル)エトキシ]フェニル}メチル)-2-(4-ヒドロキシフェニル)-3-メチル-1H-インドール-5-オールバゼドキシフェン2-(4-ヒドロキシフェニル)-3-メチル-1-[4-[2-(ヘキサヒドロ-1H-アゼピン-1-イル)エトキシ]ベンジル]-1H-インドール-5-オールBazedoxifen1-(4-(2-(Azepan-1-yl)ethoxy)benzyl)-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-olCS-1993BatoxifeneBardoxifeneUnii-Q16tt9C5bkBAZEDOXIFENE BASE
1-({4-[2-(azepan-1-yl)ethoxy]phenyl}methyl)-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol1H-Indol-5-ol, 1-((4-(2-(hexahydro-1H-azepin-1-yl)ethoxy)phenyl)methyl)-2-(4-hydroxyphenyl)-3-methyl-1-((4-(2-(azepan-1-yl)ethoxy)phenyl)methyl)-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol1-((4-(2-(azepan-1-yl)ethoxy)phenyl)methyl)-2-(4-hydroxyphenyl)-3-methylindol-5-olRefChem:116748DTXCID3096084G03XC02Viviant

物性

構造計算による物性

XLogP
6.1
極性表面積
57.9 Ų
水素結合供与体数
2
水素結合受容体数
4
回転可能結合数
7
重原子数
35
形式電荷
0
複雑度
623

実験および物理化学的性質

DrugsPharmaceuticals -> Listed in ZINC15
Human DrugsEMA approved medicines: Human medicine

物理化学的性質

融点
98 · 98-102°
沸点
694.4 · 694.4±55.0 °C(Predicted)
比重(密度)
1.19 · 1.19
貯蔵温度
-20 °C · Sealed in dry,Store in freezer, under -20°C
溶解性
クロロホルム(微量)、DMSO(微量)、メタノール(微量)
外見
個体
酸解離定数(Pka)
10.12 · 10.12±0.15(Predicted)
色
ホワイトからベリーダークベージュ

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Danger

H360 (100%): May damage fertility or the unborn child [Danger Reproductive toxicity]

P203, P280, P318, P405, and P501 (click each P-code to see the statement)

The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

危険有害性情報

Hazard Classes and CategoriesRepr. 1A (100%)

毒性情報

Adverse Effects · 1 件

Based on the results analyzed in placebo-controlled trials, the most frequent adverse effects associated with the combination of conjugated estrogens and bazedoxifene include muscle spasms, nausea, diarrhea, dyspepsia, abdominal pain, oropharyngeal pain, neck pain, and dizziness.

Toxicity SummarySigns and Symptoms of Overdose

安全データ

hs_code
2933990099

化学と産業

薬理情報

ATC Code · 2 件

G - Genito urinary system and sex hormones

QG - Genito urinary system and sex hormones

Protein Binding98-99%.
Mechanism of Action · 1 件

Bazedoxifene belongs to a class of compounds known as selective estrogen receptor modulators (SERMs). Bazedoxifene acts as both an oestrogen-receptor agonist and/or antagonist, depending upon the cell and tissue type and target genes. Bazedoxifene decreases bone resorption and reduces biochemical markers of bone turnover to the premenopausal range. These effects on bone remodelling lead to an increase in bone mineral density (BMD), which in turn contributes to a reduction in the risk of fractures. Bazedoxifene functions primarily as an oestrogen-receptor antagonist in uterine and breast tissues.

Biological Half-Life~30 hours.
Metabolism/Metabolites · 1 件

Glucuronidation is the major metabolic pathway. After peroral application, bazedoxifene is metabolized by UDP-glucuronosyltransferases (UGTs) to bazedoxifene-4'-glucuronide (M4) and bazedoxifene-5-glucuronide (M5).Little or no cytochrome P450-mediated metabolism is evident. The concentrations of this glucuronide are approximately 10-fold higher than those of unchanged active substance in plasma.

FDA Pharmacological Classification · 5 件

Q16TT9C5BK

BAZEDOXIFENE

Established Pharmacologic Class [EPC] - Estrogen Agonist/Antagonist

Mechanisms of Action [MoA] - Selective Estrogen Receptor Modulators

Bazedoxifene is an Estrogen Agonist/Antagonist. The mechanism of action of bazedoxifene is as a Selective Estrogen Receptor Modulator.

MeSH Pharmacological Classification · 2 件

A structurally diverse group of compounds distinguished from ESTROGENS by their ability to bind and activate ESTROGEN RECEPTORS but act as either an agonist or antagonist depending on the tissue type and hormonal milieu. They are classified as either first generation because they demonstrate estrogen agonist properties in the ENDOMETRIUM or second generation based on their patterns of tissue specificity. (Horm Res 1997;48:155-63)

関連反応

38 件
反応記録を作成
HRID 339140 の反応式
HRID 339140反応物として
HRID 500290 の反応式
HRID 500290生成物として
HRID 1047094 の反応式
HRID 1047094反応物として
HRID 1503309 の反応式
HRID 1503309生成物として
HRID 1503310 の反応式
HRID 1503310生成物として
HRID 1503311 の反応式
HRID 1503311生成物として
HRID 1503312 の反応式
HRID 1503312生成物として
HRID 1503313 の反応式
HRID 1503313生成物として
前へ1 / 5 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
198481-32-2
PubChem CID
154257
DTXSID
DTXSID70173593
ChEMBL
CHEMBL46740
ChEBI
CHEBI:135947
UNII
Q16TT9C5BK
EC Number
805-732-1
Nikkaji
J1.561.275D

Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS.

Absorption, Distribution and Excretion · 4 件

Bazedoxifene is rapidly absorbed with a tmax of approximately 2 hours and exhibits a linear increase in plasma concentrations for single doses from 0.5 mg up to 120 mg and multiple daily doses from 1 mg to 80 mg. The absolute bioavailability of bazedoxifene is approximately 6%.

The major route of elimination of radio-labelled bazedoxifene is the faeces, and less than 1% of the dose is eliminated in urine.

Following intravenous administration of a 3 mg dose of bazedoxifene, the volume of distribution is 14.7 ± 3.9 l/kg.

The apparent oral clearance of bazedoxifene is approximately 4 to 5 l/h/kg.

応用分野 · 2 件

用途選択的エストロゲン受容体モジュレーター(SERM)骨粗鬆症の治療薬

一般的な説明Bazedoxifene, 1-[[4-[2-(azepan-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methylindol-5-ol (Viviant), was declared to be “approvable” bythe FDA in 2007 for the prevention of postmenopausalosteoporosis. As of mid-2009, final approval in the UnitedStates is still pending. Bazedoxifene was approved inEurope in 2009 for the treatment of post–menopausalosteoporosis.

上流・下流製品情報

上流原料

1H-Indol-5-ol, 1-[[4-(2-aminoethoxy)phenyl]methyl]-2-(4-hydroxyphenyl)-3-methyl-1H-Azepine-2,7-dione, tetrahydro-1-[2-[4-[[5-hydroxy-2-(4-hydroxyphenyl)-3-methyl-1H-indol-1-yl]methyl]phenoxy]ethyl]-1H-Indol-5-ol, 2-[4-(acetyloxy)phenyl]-3-methyl-, 5-acetateアジポアルデヒド1-(4-(2-(アゼパン-1-イル)エトキシ)ベンジル)-5-(ベンジルオキシ)-2-(4-(ベンジルオキシ)フェニル)-3-メチル-1H-インドール2-(4-hydroxyphenyl)-3-Methyl-1H-indol-5-ol4-[2-(1-Azepanyl)ethoxy]benzyl chloride HClヘキサメチレンイミン